| Assessment Status | NCPE Assessment Process complete |
| HTA ID | 23045 |
| Drug | Brexucabtagene Autoleucel |
| Brand | Tecartus® |
| Indication | Adults 26 years of age and above with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia |
| Assessment Process | |
| Rapid review commissioned | 24/07/2023 |
| Rapid review completed | 10/08/2023 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of brexucabtagene autoleucel compared with the current standard-of-care. |
| Full HTA commissioned by the HSE | 31/08/2023 |
| Pre-submission consultation with Applicant | 09/10/2023 |
| Full submission received from Applicant | 18/01/2024 |
| Preliminary review sent to Applicant | 18/09/2024 |
| NCPE assessment re-commenced | 17/10/2024 |
| Factual accuracy sent to Applicant | 20/12/2024 |
| NCPE assessment re-commenced | 10/01/2025 |
| NCPE assessment completed | 23/01/2025 |
| NCPE assessment outcome | The NCPE recommends that brexu-cel not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement following confidential price negotiations. November 2025